Bayer wins FDA breakthrough therapy designation for NSCLC candidate
Pharmaceutical Technology
FEBRUARY 26, 2024
Bayer’s oral tyrosine kinase inhibitor is currently in a Phase I trial estimated to enrol 460 patients.
Pharmaceutical Technology
FEBRUARY 26, 2024
Bayer’s oral tyrosine kinase inhibitor is currently in a Phase I trial estimated to enrol 460 patients.
Bio Pharma Dive
FEBRUARY 26, 2024
Zealand shares rose by more than one-third on the data, which provide further evidence so-called incretin drugs could help treat people with the liver disease.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 26, 2024
Merck's KEYTRUDA has received a positive opinion from the EMA CHMP for use in combination with chemotherapy for non-small cell lung cancer.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 26, 2024
Do bacteria mutate randomly, or do they mutate for a purpose? Researchers have been puzzling over this conundrum for over a century. In 1943, microbiologist Salvador Luria and physicist turned biologist Max Delbrück invented an experiment to argue that bacteria mutated aimlessly.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
FEBRUARY 26, 2024
SK bioscience has achieved a significant milestone with its typhoid conjugate vaccine, SKYTyphoid, receiving WHO prequalification.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 26, 2024
The Department-related Parliamentary Standing Committee on Health and Family Welfare has recommended to the government to persuade private insurance companies to include Ayurveda, Yoga, Unani, Siddha and Homoeopathy (Ayush) treatments in their products and look at global acceptance for these systems of medicines through legalisation and insurance support in other countries.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
FEBRUARY 26, 2024
Every year, tuberculosis, malaria and HIV cause over five million deaths worldwide
Bio Pharma Dive
FEBRUARY 26, 2024
Making equipment choices with employee experience in mind can help researchers build top-performing teams while enhancing operational efficiencies.
Pharmaceutical Technology
FEBRUARY 26, 2024
The EMA's decision on the marketing authorisation application for Biogen Qalsody is expected in Q2 of this year.
Bio Pharma Dive
FEBRUARY 26, 2024
The deal would mark a retreat from public markets for the once notable biotech, which was forced to cut staff last year to save cash after trial setbacks.
Pharmaceutical Technology
FEBRUARY 26, 2024
The Phase II prospective, randomised trial will evaluate three doses of PKM-01 to select the optimal dosage for a Phase III study.
Rethinking Clinical Trials
FEBRUARY 26, 2024
Dr. Oluwaseun Adeyemi, lead author of the report Communication skills training using the EM Talk model reached a high proportion of clinicians in participating emergency departments and improved their serious illness conversation skills, according to a qualitative study conducted as part of the PRIM-ER trial. The observed reach and effectiveness of the training program has the potential to improve use of these skills in clinical practice.
Pharmaceutical Technology
FEBRUARY 26, 2024
The upcoming Clinical Trial Supply Europe 2024 conference will round-up pharma and biotech delegates to discuss the trends and challenges in clinical trial supply industry.
Pharma Times
FEBRUARY 26, 2024
Results from the study could also be used for other forms of cancer and diseases
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
FEBRUARY 26, 2024
The US FDA has granted approval for Alvotech and Teva Pharmaceuticals’ SIMLANDI injection, which is an interchangeable biosimilar to Humira.
Fierce Pharma
FEBRUARY 26, 2024
Amgen is now open for business in Central Ohio after cutting the ribbon at its “most advanced facility to date.” | Amgen is now open for business in Central Ohio after cutting the ribbon at its “most advanced facility to date.” Dubbed “Amgen Ohio,” the nearly 300,000-square-foot biomanufacturing plant in New Albany, Ohio, is set to employ 400 full-time employees and leverage the “latest innovation and technology.
Pharmaceutical Technology
FEBRUARY 26, 2024
Moderna has announced the conclusion of construction works at its new mRNA manufacturing facility in Canada.
Fierce Pharma
FEBRUARY 26, 2024
Bristol Myers Squibb’s first drug substance facility outside the United States is now set to become the company’s inaugural sterile drug product (SDP) facility in Europe, thanks to a multi-million- | Bristol Myers Squibb’s first drug substance facility outside the United States is now set to become the company’s inaugural sterile drug product (SDP) facility in Europe, thanks to a multi-million-dollar expansion expected to add hundreds of new jobs in the coming years.
Bio Pharma Dive
FEBRUARY 26, 2024
The drug, one of several GSK is developing for drug-resistant bacteria, has now succeeded in testing against two different infections.
Fierce Pharma
FEBRUARY 26, 2024
Not even one year after becoming a commercial biotech, Krystal Biotech has blockbuster dreams for its flagship product. | In its first six months of commercial availability, Krystal's topical gene therapy Vyjuvek raked in more than $50 million. Now, the company is looking toward bringing the drug to Europe and Japan and testing a new eye-drop formulation.
pharmaphorum
FEBRUARY 26, 2024
Digital health company Akili expands beyond the US as partner Shionogi files for approval for its ADHD digital therapeutic (DTx) in Japan
Fierce Pharma
FEBRUARY 26, 2024
The chilling wind of the biotech winter has apparently spared BeiGene. | The chilling wind of the biotech winter has apparently spared BeiGene. While layoffs have been commonplace in the industry, BeiGene employed 1,400 more people at the beginning of 2024 than it did a year ago.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
FEBRUARY 26, 2024
Sanofi gets a win for its oral BTK inhibitor rilzabrutinib in chronic hive disorder CSU, setting up a phase 3 programme as it chases after Novartis’ remibrutinib in this indication.
Fierce Pharma
FEBRUARY 26, 2024
For the third straight year, Sanofi CEO Paul Hudson has seen a slight dip in his compensation. | For the third straight year, Sanofi CEO Paul Hudson has seen a slight dip in his compensation. For 2023, Hudson will receive 10.57 million euros ($11.44 million) in total pay, according to the company’s annual filing.
pharmaphorum
FEBRUARY 26, 2024
GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea.
Drug Patent Watch
FEBRUARY 26, 2024
Switching pharmaceutical excipients, the inactive components used in drug formulations, can have significant implications for both production costs and market appeal. These components, while not contributing directly to the therapeutic… The post Cost-Cut Without Compromise: Navigating Excipient Switching in Pharma appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
FEBRUARY 26, 2024
Boehringer Ingelheim and Zealand Pharma report stellar top-line results for GLP-1/glucagon agonist survodutide in liver disease MASH.
XTalks
FEBRUARY 26, 2024
The US Food and Drug Administration (FDA) has granted expanded approval to Genentech’s (part of Roche) Xolair (omalizumab) to help reduce allergic reactions to various foods after accidental exposure. The approval is indicated for reducing Type 1 allergic reactions, known as immediate reactions mediated by immunoglobulin E (IgE), in certain adults and children one year of age or older after accidental exposure to one or more foods.
pharmaphorum
FEBRUARY 26, 2024
AstraZeneca has moved a step closer to EU approval of oral Factor D inhibitor danicopan in the EU, after the EMA’s human medicines committee, the CHMP, backed the drug as a treatment for residual haemolytic anaemia in patients with paroxysmal nocturnal haemoglobinuria (PNH).
Pharmaceutical Technology
FEBRUARY 26, 2024
Access and buy GlobalData’s databook on the latest filings and grants activity for Vir Biotechnology here.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content